1. At a Glance – Blink and You’ll Miss the Irony
Sagility India Limited is what happens when Wall Street healthcare meets Bengaluru back office efficiency. Listed at ₹51.7 with a market cap of ₹24,189 crore, Sagility has quietly become one of the largest pure-play US healthcare outsourcing companies listed in India.
Q3 FY26 numbers came in hot: quarterly revenue of ₹1,971 crore (+35.6% YoY), PAT of ₹268 crore (+34.6% YoY), and EBITDA margins holding steady at ~26%. Sounds sexy, right? But then you look at ROCE (9.6%) and ROE (7.4%) and suddenly the excitement needs a cold shower.
Three-month return? -5.3%. Six-month return? +15%. Promoters? Busy selling. FIIs and DIIs? Busy buying. This stock is literally a live panel discussion between “growth story” and “valuation hangover.”
So is Sagility a long-term healthcare compounder hiding in plain sight, or just another ITES story with great margins and mediocre capital efficiency? Let’s autopsy the numbers.
2. Introduction – The US Healthcare ATM Nobody Talks About
Sagility operates in one of the most boring yet lucrative industries imaginable: US healthcare administration. Claims. Eligibility. Billing. Audits. Things patients hate, insurers need, and hospitals outsource faster than you can say “prior authorization denied.”
Incorporated in 2021 (yes, technically a baby), Sagility is actually an old soul. Its top five client groups have been around for an average of 17 years. That’s longer than most Indian startups’ entire life cycle.
The company serves only US clients, which means zero India exposure risk, full USD billing, and full exposure to American policy drama. From ACA rule changes to excise tax threats, Sagility sits right in the blast radius — and yet keeps growing at 30%+ topline.
But here’s the fun part: despite processing 105 million claims annually and managing 75 million member/provider interactions, Sagility still holds only 1.23% market share of the US healthcare outsourcing market. This is a giant ocean with a small but
